Unique cancer arising after anti-CD19 CAR-T cell therapy Representative micrographs demonstrate the phenotypic difference inbetween lymphoid and myeloid cancer cells. After anti-CD19 CAR-T cell therapy all patients achieved remission of B-cell ALL; however, in two cases patients relapsed with myeloid malignancies. Immunotherapy represents a fresh wave of cancer therapies that are just injecting clinics or presently in trial. This treatment…